Developmental and epileptic encephalopathies (DEEs) are a group of childhood-onset
epilepsy syndromes characterized by frequent seizures, severe cognitive and behavioral …

Thalamic neuromodulation has emerged as a treatment option for drug-resistant epilepsy
(DRE) with widespread and/or undefined epileptogenic networks. While deep brain …

Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy
characterized by multiple drug-resistant seizure types, cognitive impairment, and distinctive …

Epilepsy affects more than 70 million individuals of all ages worldwide and remains one of
the most severe chronic noncommunicable neurological diseases globally. Several …

Dravet syndrome (DS) is a severe genetic developmental and epileptic encephalopathy,
primarily caused by SCN1A gene mutations. Historically, treatments like clobazam and …

Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy
marked by drug-resistant seizures and profound cognitive and behavioral impairments, with …

While neuromodulation devices for managing neurological conditions have significantly
advanced, there remains a substantial gap in FDA-approved devices specifically designed …

OBJECTIVE Patients with drug-resistant epilepsy (DRE) are often referred for phase II
evaluation with stereo-electroencephalography (SEEG) to identify a seizure onset zone for …

Drug-resistant epilepsy remains a substantial challenge in neurology, affecting patients who
do not respond to conventional antiepileptic drugs. Responsive neurostimulation (RNS) has …

A variety of treatment modalities currently exist for epilepsy, a debilitating disorder. With the
emergence of drug-resistant epilepsy, however, new options are being explored. Deep brain …